Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.69
+4.3%
$1.61
$0.98
▼
$1.86
$1.20B1.523.36 million shs3.06 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
OPKO Health, Inc. stock logo
OPK
OPKO Health
+4.32%-1.17%+4.97%+15.75%+32.03%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.69
+4.3%
$1.61
$0.98
▼
$1.86
$1.20B1.523.36 million shs3.06 million shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
OPKO Health, Inc. stock logo
OPK
OPKO Health
+4.32%-1.17%+4.97%+15.75%+32.03%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.43
Hold$3.42102.17% Upside

Current Analyst Ratings Breakdown

Latest OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingSell (D-)
11/6/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
DowngradeStrong-Buy ➝ Hold
10/16/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Set Price Target$4.00
10/16/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingBuy
10/16/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingBuy
10/16/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
Reiterated RatingOverweight$3.00 ➝ $4.00
10/16/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeMarket Perform ➝ Outperform$2.25
9/28/2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
UpgradeHold ➝ Strong-Buy
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M2.07N/AN/A$1.50 per share1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.19N/AN/AN/A-29.51%-10.90%-6.93%N/A

Latest OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.0680-$0.07-$0.0020-$0.07$136.62 million$130.83 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.41
4.97
4.65

Institutional Ownership

CompanyInstitutional Ownership
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%

Insider Ownership

CompanyInsider Ownership
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373742.51 million410.46 millionOptionable

Recent News About These Companies

MiniMed Launches MiniMed Flex Pump in Europe to Expand Diabetes Care
HNGE Stock Surges Nearly 146% YTD: Can Its Growth Story Continue?
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
J.P. Morgan Sticks to Its Hold Rating for Opko Health (OPK)
OPKO Health stock: Labcorp deal reshapes biotech strategy
OPKO Health (NASDAQ:OPK) Shares Down 4.4% - What's Next?
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
OPKO Health Stock Earnings Estimates Lifted by HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.69 +0.07 (+4.32%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.66 -0.03 (-1.78%)
As of 11/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.